Resultados globales: 13 registros encontrados en 0.01 segundos.
Artículos, Encontrados 8 registros
Documentos de investigación, Encontrados 5 registros
Artículos Encontrados 8 registros  
1.
15 p, 3.9 MB Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection / Guillén Montalbán, Yolanda. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Noguera-Julian, Marc (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Rivera Pinto, Javier (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Casadellà, Maria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Zevin, Alexander (University of Washington) ; Rocafort, M. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Parera, M. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Rodríguez, C. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Arumí, M. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Carrillo, Jorge (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Mothe, Beatriz. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Estany Quera, Carla (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Coll, J. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Bravo, I. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Herrero, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Saz, J. (BCN Checkpoint) ; Sirera, Guillem (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Torrella Domingo, Adriana (Hospital Universitari Vall d'Hebron) ; Navarro Mercadé, Jordi (Hospital Universitari Vall d'Hebron) ; Crespo, M. (Infectious Diseases Unit. Internal Medicine Department. Complexo Hospitalario Universitario. Vigo. IIS Galicia Sur) ; Negredo Puigmal, Eugènia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Brander, Christian. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Blanco, Julià (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Calle, M.L. (Universitat de Vic - Universitat Central de Catalunya) ; Klatt, N.R. (University of Washington) ; Pérez-Álvarez, Núria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Paredes, Roger (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Universitat Autònoma de Barcelona
Human immunodeficiency virus (HIV)-1 infection causes severe gut and systemic immune damage, but its effects on the gut microbiome remain unclear. Previous shotgun metagenomic studies in HIV-negative subjects linked low-microbial gene counts (LGC) to gut dysbiosis in diseases featuring intestinal inflammation. [...]
2019 - 10.1038/s41385-018-0083-7
Mucosal Immunology, Vol. 12 Núm. 1 (january 2019) , p. 232-246  
2.
11 p, 1.6 MB Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 / Eron, J.J. (University of North Carolina School of Medicine) ; Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ; Cunningham, D. (Pueblo Family Physicians) ; Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Post, F. (King's College Hospital NHS Foundation Trust) ; De Wit, S. (Saint-Pierre University Hospital. Université Libre de Bruxelles) ; Lathouwers, E. (Janssen Pharmaceutica NV) ; Hufkens, V. (Janssen Pharmaceutica NV) ; Jezorwski, J. (Janssen Research & Development) ; Petrovic, R. (Janssen Pharmaceutica NV) ; Brown, K. (Janssen Pharmaceutica NV) ; Van Landuyt, E. (Janssen Pharmaceutica NV) ; Opsomer, M. (Janssen Pharmaceutica NV) ; De Wit, S. (Saint-Pierre University Hospital. Université Libre de Bruxelles) ; Florence, E. (Institute of Tropical Medicine) ; Moutschen, M. (Infectious Diseases department. Liège University Hospital) ; Van Wijngaerden, E. (Department of General Internal Medicine. University Hospitals. KU Leuven - University of Leuven) ; Vandekerckhove, L. (Ghent University and Ghent University Hospital) ; Vandercam, B. (AIDS Reference center. Cliniques Universitaires Saint-Luc) ; Brunetta, J. (Maple Leaf Medical Clinic) ; Conway, B. (Vancouver Infectious Diseases Center) ; Klein, M. (Division of Infectious Diseases. Faculty of Medicine. McGill University Health Centre) ; Murphy, D. (Institut national de santé publique du Québec) ; Rachlis, A. (Sunnybrook Health Sciences Centre) ; Shafran, S. (Department of Medicine. University of Alberta) ; Walmsley, S. (University Health Network) ; Ajana, F. (Infectious Diseases Department. Tourcoing Hospital) ; Cotte, L. (Hospices Civils de Lyon. Hôpital de la Croix-Rousse) ; Girardy, P.M. (University Pierre & Marie Curie) ; Katlama, C. (HIV Clinical Research Unit) ; Molina, J.M. (Department of Infectious Diseases. St-Louis Hospital APHP. University of Paris Diderot) ; Poizot-Martin, I. (Clinical Immuno-Hematology Department. Aix-Marseille University. Sainte-Marguerite University Hospital and Inserm U912) ; Raffi, F. (CHU Hôtel Dieu) ; Rey, D. (Le Trait d'Union. HIV-Infection Care Center. Hôpitaux Universitaires de Strasbourg) ; Reynes, J. (Montpellier University Hospital) ; Teicher, E. (Infectious Diseases Department. APHP. Hôpital Bicêtre) ; Yazdanpanah, Y. ; Gasiorowski, J. (Independent Laboratory for Monitoring Infections among Drug Users at the Department of Infectious Diseases. Liver Disease and Acquired Immune Deficiencies. Wroclaw Medical University) ; Halota, W. (Department of Infectious Diseases and Hepatology. Nicolaus Copernicus University) ; Horban, A. (Medical University of Warsaw. Department for Adult's Infectious Diseases) ; Piekarska, A. (Department of Infectious Diseases and Hepatology. Medical University of Lodz) ; Witor, A. (Regional Hospital. Out-Patient's Clinic for Immune Deficiency) ; Arribas, J.R. (Hospital Universitario La Paz. IdiPAZ) ; Perez-Valero, I. (Department of La Paz Hospital) ; Berenguer, J. (Hospital General Universitario Gregorio Marañón) ; Casado, J. (Department of Infectious Diseases. Ramon y Cajal Hospital) ; Gatell, J.M. (Infectious Diseases Department. HCB) ; Gutiérrez, Félix (Infectious Diseases Unit. Hospital Universitario de Elche) ; Galindo, M.J. (Hospital Clínic Universitari (València)) ; Gutiérrez Macià, Mª Del Mar (Institut d'Investigació Biomèdica Sant Pau) ; Iribarren, J.A. (Hospital Universitario Donostia) ; Knobel, H. (Hospital del Mar (Barcelona, Catalunya)) ; Negredo Puigmal, Eugènia. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Pineda, J.A. (Unit of Infectious Diseases and Microbiology. Hospital Universitario de Valme) ; Podzamczer, D. (Institut d'Investigació Biomèdica de Bellvitge) ; Sogorb, J.P. (HIV Unit. Hospital 12 de Octubre. imas12. UCM) ; Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Ricart, C. (Department of Microbiology. School of Medicine. University of Valencia) ; Rivero, A. (Infectious Diseases Unit. Hospital Universitario Reina Sofía. Instituto Maimonides de Investigación Biomedica de Córdoba IMIBIC Cordoba University) ; Santos Gil, I. (Unidad de Enfermedades Infecciosas. Hospital Universitario de la Princesa) ; Blaxhult, A. (Department of Infectious Diseases. Venhälsan. Södersjukhuset) ; Flamholc, L. (Department of Infectious Diseases. Malmö University Hospital) ; Gisslèn, M. (Department of Infectious Diseases. University of Gothenburg) ; Thalme, A. (Department of Infectious Diseases. Karolinska University Hospital) ; Fehr, J. (Division of Infectious Diseases and Hospital Epidemiology. University Hospital Zurich) ; Rauch, A. (Department of Infectious Diseases. Bern University Hospital Inselspital. University of Bern) ; Stoeckle, M. (Division of Infectious Diseases and Hospital Epidemiology. Departments of Medicine and Clinical Research. University Hospital of Basel and University of Basel) ; Clarke, A. (Claude Nicol Centre. Royal Sussex County Hospital. Brighton and Sussex University Hospitals NHS Trust) ; Gazzard, B.G. (St. Stephen's Centre. Department of HIV/Genito-Urinary Medicine. Chelsea and Westminster Hospital) ; Johnson, M.A. (Queen Mary University) ; Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ; Post, F. (King's College Hospital NHS Foundation Trust) ; Ustianowski, A. (Regional Infectious Diseases Unit. North Manchester General Hospital) ; Waters, L. (University College London Hospital) ; Bailey, J. (Department of Medicine. Johns Hopkins University School of Medicine) ; Benson, P. (Be Well Medical) ; Bhatti, L. (AIDS Healthcare Foundation) ; Brar, I. (Henry Ford Hospital) ; Bredeek, U.F. (Metropolis Medical PC) ; Brinson, C. (Central Texas Clinical Research) ; Crofoot, G. (The Crofoot Research Center) ; Cunningham, D. (Pueblo Family Physicians) ; DeJesus, E. (Pueblo Family Physicians) ; Dietz, C. (Orlando Immunology Center) ; Dretler, R. (HIV Medicine. Kansas City Free Health Clinic) ; Eron, J. (Infectious Disease Specialists of Atlanta) ; Felizarta, F. (Private Practice) ; Fichtenbaum, C. (University of Cincinnati College of Medicine) ; Gallant, J. (Southwest CARE Center) ; Gathe, J. (Therapeutic Concepts) ; Hagins, D. (Georgia Department of Public Health. Chatham Care Center) ; Henn, S. (Whitman-Walker Health) ; Henry, W.K. (Department of Medicine. University of Minnesota Washington University School of Medicine) ; Huhn, G. (Ruth M. Rothstein CORE Center) ; Jain, M. (Department of Internal Medicine. University of Texas Southwestern Medical Center) ; Lucasti, C. (South Jersey Infectious Disease) ; Martorell, C. (Infectious Disease and The Research Institute) ; McDonald, C. (Tarrant County Infectious Disease Associates) ; Mills, A. (Southern California Men's Medical Group) ; Morales-Ramirez, J. (Clinical Research Puerto Rico Inc.) ; Mounzer, K. (Philadelphia FIGHT) ; Nahass, R. (ID Care) ; Olivet, H. (Community Research Initiative of New England) ; Osiyemi, O. (Triple O Research Institute PA) ; Prelutsky, D. (Department of Internal Medicine. Washington University School of Medicine) ; Ramgopal, M. (Midway Immunology Center. Fort Pierce) ; Rashbaum, B. (Capital Medical Associates) ; Richmond, G. (Broward General Medical Center) ; Ruane, P. (Ruane Clinical Research Group) ; Scarsella, A. (Pacific Oaks Medical Group) ; Scribner, A. (DCOL Center for Clinical Research) ; Shalit, P. (Peter Shalit MD and Associates) ; Shamblaw, D. (La Playa Medical Group) ; Slim, J. (Department of Infectious Diseases. Seton Hall University) ; Tashima, K. (The Miriam Hospital. Warren Alpert Medical School of Brown University) ; Voskuhl, G. (AIDS Arms. Inc.) ; Ward, D. (Dupont Circle Physicians Group) ; Wilkin, A. (Wake Forest School of Medicine) ; de Vente, J. (Living Hope Foundation) ; Universitat Autònoma de Barcelona
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. [...]
2019 - 10.1016/j.antiviral.2019.104543
Antiviral Research, Vol. 170 (october 2019) , p. 104543  
3.
7 p, 628.1 KB Clinical and Emotional Factors Related to Erectile Dysfunction in HIV-Infected Men / Fumaz, Carmina R. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Ayestaran, Aintzane (Universitat Politècnica de Catalunya) ; Perez-Alvarez, Nuria (Universitat Politècnica de Catalunya) ; Muñoz-Moreno, Jose A. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Ferrer, Maria Jose (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Negredo Puigmal, Eugènia (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Clotet, Bonaventura (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Universitat Autònoma de Barcelona
The prevalence and associated factors of erectile dysfunction (ED) in Human Immunodeficiency Virus (HIV)-infected men remain controversial. The authors evaluated ED, clinical, and emotional variables in a group of 501 HIV-infected men in a cross-sectional 4-month observational study. [...]
2016 - 10.1177/1557988316669041
American Journal of Men's Health, Vol. 11 (september 2016) , p. 647-653  
4.
12 p, 2.8 MB Gut microbiota linked to sexual preference and HIV infection / Noguera-Julian, Marc (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Rocafort, Muntsa (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Guillén, Yolanda (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Rivera, Javier (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Casadellà, Maria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Nowak, Piotr (Karolinska Universitetssjukhuset) ; Hildebrand, Falk (European Molecular Biology Laboratory) ; Zeller, Georg (European Molecular Biology Laboratory) ; Parera, Mariona (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Bellido, Rocío (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Rodríguez, Cristina (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Carrillo, Jorge (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Mothe, Beatriz (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Coll, Josep (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Bravo, Isabel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Estany, Carla (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Herrero, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Saz, Jorge (BCN Checkpoint) ; Sirera, Guillem (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Torrela, Ariadna (Hospital Universitari Vall d'Hebron) ; Navarro, Jordi (Hospital Universitari Vall d'Hebron) ; Crespo, Manel (Hospital Universitari Vall d'Hebron) ; Brander, Christian (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Negredo Puigmal, Eugènia (Universitat de Vic) ; Blanco, Julià (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Guarner, Francisco (Hospital Universitari Vall d'Hebron) ; Calle, Maria Luz (Universitat de Vic) ; Bork, Peer (European Molecular Biology Laboratory) ; Sönnerborg, Anders (Karolinska Universitetssjukhuset) ; Clotet, Bonaventura (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Paredes, Roger (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
The precise effects of HIV-1 on the gut microbiome are unclear. Initial cross-sectional studies provided contradictory associations between microbial richness and HIV serostatus and suggested shifts from Bacteroides to Prevotella predominance following HIV-1 infection, which have not been found in animal models or in studies matched for HIV-1 transmission groups. [...]
2016 - 10.1016/j.ebiom.2016.01.032
EBioMedicine, Vol. 5 (March 2016) , p. 135-146  
5.
1 p, 76.3 KB Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC / Ramón Santos, José (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Saumoy, María (Hospital Universitari Vall d'Hebron) ; Bravo, Isabel (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Navarro, Jordi (Hospital Universitari Vall d'Hebron) ; Estany, Carla (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Podzamczer, Daniel (Hospital Universitari de Bellvitge) ; Ribera, Esteban (Hospital Universitari Vall d'Hebron) ; Negredo Puigmal, Eugènia (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Clotet, Bonaventura (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Paredes, Roger (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Universitat Autònoma de Barcelona
Previous studies have described improvements on lipid parameters when switching from other antiretroviral drugs to tenofovir (TDF) and impairments in lipid profile when discontinuing TDF. [-] It is unknown, however, if TDF has an intrinsic lipid-lowering effect or such findings are due to the addition or removal of other offending agents or other reasons. [...]
2014 - 10.7448/IAS.17.4.19550
Journal of the International AIDS Society, Vol. 17 (november 2014)  
6.
11 p, 1.1 MB Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery / Massanella Luna, Marta, 1983- (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Gómez-Mora, Elisabet (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Carrillo, Jorge (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Curriu Martí, Marta (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Ouchi, Dan (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Puig, Jordi (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Negredo Puigmal, Eugènia (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Cabrera Navarro, Cecilia (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Clotet, Bonaventura (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Blanco Arbués, Julià (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Universitat Autònoma de Barcelona
BACKGROUND: High levels of ex vivo CD4 T-cell death and the accumulation of highly differentiated and/or immunosenescent T cells have been associated with poor CD4 T-cell recovery in treated HIV-infected individuals. [...]
2015 - 10.1186/s12967-015-0601-2
Journal of translational medicine, Vol. 13 (July 2015) , article 33  
7.
19 p, 76.2 KB Interruptions of antiretroviral therapy in human immunodeficiency virus infection : are they detrimental to neurocognitive functioning? / Muñoz-Moreno, Jose Antonio (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Fumaz, Carmina R. (Rodríguez Fumaz) (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Prats, Anna (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Ferrer, Maria J. (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Negredo Puigmal, Eugènia (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Pérez-Álvarez, Núria (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Moltó, José (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Gómez Melis, Guadalupe (Universitat Politècnica de Catalunya) ; Garolera i Freixa, Maite (Consorci Sanitari Hospital de Terrassa) ; Clotet, Bonaventura (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Universitat Autònoma de Barcelona
Background: Since interruptions of antiretroviral treatment may entail clinical risks for HIV-infected individuals, we investigated their impact on neurocognitive functioning. Methods: Cross-sectional study comparing HIV-infected persons who had interrupted antiretroviral therapy in the past (interruption group, IG) with persons who had never discontinued therapy (non-interruption group, NIG). [...]
2010
Journal of Neurovirology, Vol. 16, Issue 3 (May 2010) , p. 208-218
6 documentos
8.
7 p, 502.3 KB Classification models for neurocognitive impairment in HIV Infection based on demographic and clinical variables / Muñoz-Moreno, Jose Antonio (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Pérez-Álvarez, Núria (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Muñoz-Murillo, Amalia (Universitat de Barcelona) ; Prats, Anna (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Garolera i Freixa, Maite (Consorci Sanitari Hospital de Terrassa) ; Jurado, Ma. Ángeles (María Ángeles) (Universitat de Barcelona) ; Fumaz, Carmina R. (Rodríguez Fumaz) (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Negredo Puigmal, Eugènia (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Ferrer, Maria J. (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Clotet, Bonaventura (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Universitat Autònoma de Barcelona
Objective: We used demographic and clinical data to design practical classification models for prediction of neurocognitive impairment (NCI) in people with HIV infection. Methods: The study population comprised 331 HIV-infected patients with available demographic, clinical, and neurocognitive data collected using a comprehensive battery of neuropsychological tests. [...]
2014 - 10.1371/journal.pone.0107625
PloS one, Vol. 9 Issue 9 (September 2014) , p. e107625  

Documentos de investigación Encontrados 5 registros  
1.
143 p, 3.4 MB Influencia de factores biopsicosociales sobre el estado de salud de las personas con infección por el VIH y/o el VHC en España / Martínez Batlle, Francisco ; Negredo Puigmal, Eugènia, dir. ; Tor Aguilera, J, dir. ; Universitat Autònoma de Barcelona. Departament de Medicina
El enfoque exclusivamente biomédico en el abordaje de las enfermedades es una estrategia que se ha mostrado insuficiente en muchas ocasiones, especialmente en aquellas patologías que conllevan una carga de estigma y discriminación como la infección por el virus de la inmunodeficiencia humana (VIH) o, en determinados subgrupos poblacionales tales como los usuarios de drogas intravenosas, la causada por el virus de la hepatitis C (VHC). [...]
The exclusively biomedical approach to dealing with diseases is a paradigm that has proven insufficient on many occasions, especially in those pathologies that carry a burden of stigma and discrimination, such as infection with the human immunodeficiency virus (HIV) or -in certain population subgroups such as intravenous drug users - that caused by the hepatitis C virus (HCV). [...]

[Barcelona] : Universitat Autònoma de Barcelona, 2019.  
2.
207 p, 2.8 MB Estudio metabólico y cardiovascular en una cohorte de pacientes infectados por el VIH-1 : : predisposición genética, aterosclerosis subclínica y eventos coronarios / Echeverría Bermúdez, Joan Patricia ; Negredo Puigmal, Eugènia, dir. ; Clotet, Bonaventura, dir. ; Tor Aguilera, J. ; Universitat Autònoma de Barcelona. Departament de Medicina
La incidencia de la enfermedad cardiovascular (ECV) se ha incrementado en los pacientes infectados por el VIH. La replicación del VIH y la terapia antirretroviral pueden contribuir de forma independiente al aumento del riesgo de ECV. [...]
The incidence of cardiovascular disease (CVD) has increased among HIV-infected patients. Both HIV replication and antiretroviral therapy may contribute independently to increase the risk of CVD. However, the cause of this increased risk is multifactorial. [...]

Bellaterra : Universitat Autònoma de Barcelona, 2015  
3.
29 p, 483.9 KB Suboptimal Management of Coronary Risk in Daily Clinical Practice : Results from a Mediterranean Cohort of HIV-Infected Patients With Myocardial Infarction / Echeverría Bermúdez, Joan Patricia ; Clotet, Bonaventura, dir. (Universitat Autònoma de Barcelona. Departament de Medicina) ; Negredo Puigmal, Eugènia, dir. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona. Departament de Medicina ; Universitat Autònoma de Barcelona. Facultat de Medicina
Background: The incidence of cardiovascular events in HIV patients has fallen. Methods: We identified 81 patients with a history of coronary events from 2 hospitals in Spain to evaluate management of CVRF before and after the event. [...]
Introducció: La incidència de malalties cardiovasculars en pacients VIH han disminuït. Mètode: Vam identificat 81 pacients amb malalties coronaris de 2 hospitals a Espanya per avaluar la gestió dels FRCV abans i després de la malaltia. [...]

2012  
4.
213 p, 729.1 KB Estratègies de simplificació del tractament antiretroviral en diferents estadiatges de la infecció pel VIH-1 / Bonjoch Badia, Anna ; Negredo Puigmal, Eugènia, dir. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Clotet, Bonaventura, dir. (Universitat Autònoma de Barcelona. Departament de Medicina)
La generalització del tractament antiretroviral de gran activitat (TARGA) va canviar profundament la perspectiva de la infecció pel VIH-1. Amb la incorporació de nous agents terapèutics es va fer possible el control de la replicació viral, el que va repercutir en un allargament en la perspectiva vital dels pacients infectats pel VIH-1. [...]
The generalization of highly active antiretroviral therapy (HAART) radically changed the perspective of HIV-1. With the addition of new therapeutic agents made possible the control of viral replication which resulting in greater control of clinical progression and a lengthening in life perspective of patients infected by HIV-1, being of vital importance that the established treatment for infection control was carried out continuously. [...]

Bellaterra : Universitat Autònoma de Barcelona, 2009  
5.
94 p, 769.7 KB Terapias de simplificación en pacientes con infección por el virus de la inmunodeficiencia humana y su impacto metabólico / Negredo Puigmal, Eugènia ; Clotet, Bonaventura, dir. (Universitat Autònoma de Barcelona. Departament de Medicina)
El tratamiento antirretroviral de alta eficacia ha reducido drásticamente la morbi-mortalidad de los pacientes con infección por el VIH al conseguir una supresión mantenida del virus. Sin embargo, la erradicación de éste es aún un objetivo a alcanzar y por tanto, por el momento, la terapia antirretroviral debe mantenerse de forma indefinida. [...]
The eradication of HIV infection is unattainable at present in the clinical setting despite the initial expectations derived from the ability of highly active antiretroviral therapy (HAART) to profoundly suppress viral replication and to limit morbidity and mortality of HIV/AIDS disease. [...]

Bellaterra : Universitat Autònoma de Bellaterra, 2003  

Vea también: autores con nombres similares
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.